FDA Nonprescription Drugs and Arthritis Advisory Committees to meet jointly July 15.
This article was originally published in The Tan Sheet
Executive Summary
NONPRESCRIPTION DRUGS AND ARTHRITIS ADVISORY COMMITTEES JOINT MEETING is scheduled for July 15. The possibility of treating migraines in the OTC setting is slated as the topic for discussion. One candidate for the new OTC indication is said to be Bristol-Myers Squibb's established nonprescription analgesic Excedrin Extra Strength, which contains acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg per dose.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning